retatrutide in europe ESC 2024: improves lipid and cardiovascular risk profile Phase II trial Retatrutide demonstrates significant weight loss

A notable proportion of patients with NAFLD progress to non-alcoholic steatohepatitis (NASH), a more severe form characterized by hepatic inflammation and varying degrees of fibrosis

GLP-1 medications are usually not covered for patients with PCOS, because the prescription is not FDA-approved for that condition

Without adequate muscle, your body is burning fewer calories, which can lead to weight gain unless you drastically reduce your caloric intakesomething that isnt sustainable for most people

doi:10.1023/A:1021922305036 Malaguarnera M, Pistone G, Astuto M, Vecchio I, Raffaele R, Lo Giudice E, Rampello L (2006) Effects of Lacetylcarnitine on cirrhotic patients with hepatic coma: randomized double-blind, placebo-controlled trial

Peptide therapy is not right for everyone